DAVID OLIVIER,BOULTON CRAIG,DE VERA ANA,DUMORTIER THOMAS,HUNT IRENE,SCHMOUDER ROBERT,BURTIN PASCALE
申请号：
NZ59853410
公开号：
NZ598534A
申请日:
2010.09.20
申请国别(地区):
NZ
年份:
2014
代理人:
摘要：
NZ 598534 Disclosed is the use of a therapeutically effective amount of a S1P receptor modulator or agonist, which is fingolimod in free form, in pharmaceutically acceptable salt form or fingolimod phosphate, in the manufacture of a medicament for treating an inflammatory or autoimmune disease or disorder in a patient in need thereof, wherein the adverse events possibly associated with administering said S1P receptor modulator or agonist are controlled, limited or abolished, wherein said medicament is adapted for administration to a patient that is monitored, before or during a specific period of time after the first administration of said medicament wherein the monitoring comprises step a) and step b)； step a and step c)； or steps a) and b) and c), where the steps a), b) and c) are defined as follows: a) monitoring and/or recording heart rate or blood pressure； b) testing history of viral infection or viral serology； c) monitoring and/or recording of infections or infestations； wherein the monitoring and/or recording may indicate that the administration of the medication to the patient should be interrupted and/or modified and/or a second drug should be administered which mitigates said adverse effects.
